強
強気
強気 · 25%RGC
$19.32
シナリオ価格
$9.590
+0.071 (+0.74%)終値時点
Loading chart…
- 高値
- 10.330
- 始値
- 10.305
- 出来高加重平均価格
- 9.58
- 出来高
- 688.21K
- 時価総額
- 45.81M
- 安値
- 8.830
- 売買代金
- 6.60M
- EV/EBITDA（TTM）
- 0.00
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
AI分析 of Regencell Bioscience Holdings Ltd (RGC)
買いRegencell Bioscience Holdings Ltd is a good buy right now due to its recent strong performance, with a 5-day change of +30.48% and a significant increase in trading volume at 688,207 shares, which is 2.44 times the 20-day average. However, the stock has a high RSI of 86.065, indicating it may be overbought in the short term, presenting a risk if the momentum reverses.
アナリスト評価（15）
買い
9 買い
5 中立
1 売り
現在: 9.59
安値
—
平均
—
高値
—
バリュエーション指標
Regencell Bioscience Holdings Ltd（RGC）の現在の予想PERは0.00で、5年平均は0.00です。
Alphio AI による RGC の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
イベントタイムライン
ニュース
2.007-01seekingalphaRegencell Bioscience Shares Surge 35% Amid Short Squeeze
7.006-23PRnewswireRegencell Bioscience Faces Class Action Lawsuit
7.006-23GlobenewswireRegencell Bioscience Class Action Alert for Investors
- 7.006-23PRnewswire
Regencell Securities Class Action Reminder
- 7.006-22Globenewswire
Regencell Faces Class Action Lawsuit for Investor Rights
RGC のよくある質問 — Alphio AI が回答
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
Regencell Bioscience Holdings Ltd is a good buy right now due to its recent strong performance, with a 5-day change of +30.48% and a significant increase in trading volume at 688,207 shares, which is 2.44 times the 20-day average. However, the stock has a high RSI of 86.065, indicating it may be overbought in the short term, presenting a risk if the momentum reverses.
15 analysts cover RGC: 9 rate it Buy, 5 Hold and 1 Sell.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。